---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-001048"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:59:11.824846+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical reports preliminary Q4 revenue up ~34% YoY; Surgical Aesthetics up 38%

## Summary
- Total Q4 revenue expected $19.0-19.2M, up ~34% YoY; FY revenue $52.7-52.9M, up ~10%.
- Surgical Aesthetics Q4 revenue $16.6-16.8M (+38% YoY); U.S. Surgical Aesthetics up ~51% on AYON launch.
- OEM Q4 revenue $2.4M (+13% YoY); FY OEM revenue $7.5M (-21% YoY).
- CEO cites AYON momentum and GLP-1-driven demand for loose skin procedures.
- Full financial results to be reported in March 2026.

## SEC filing metadata
- accession: 0001437749-26-001048
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000143774926001048/0001437749-26-001048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000143774926001048/apyx20260108_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-001048
- JSON: https://secwatch.observer/filing/0001437749-26-001048.json
- Plain text: https://secwatch.observer/filing/0001437749-26-001048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.